Results 241 to 250 of about 203,911 (301)
Abstract Gastric inhibitory polypeptide (GIP)/Glucagon‐like peptide‐1 (GLP‐1) receptor agonists are increasingly prescribed for the management of obesity and type 2 diabetes, yet research pertinent to their effects on muscle health is limited. Considering the central role of muscle strength as a sarcopenia component, this article summarizes emerging ...
Konstantinos Prokopidis
wiley +1 more source
Management of chronic kidney disease in a 65-year-old man with diabetes. [PDF]
Dubrofsky L, Cherney DZI, Odutayo A.
europepmc +1 more source
Cost-effectiveness of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists for patients with high cardiovascular risk and type 2 diabetes in Canada. [PDF]
McNally ES +9 more
europepmc +1 more source
Is there still room for pioglitazone in contemporary type 2 diabetes management? [PDF]
Caruso I.
europepmc +1 more source
Successful Resuscitation of Anaphylactic Shock With Central Nervous System Dysfunction in a Patient on Multiple Antihypertensive Therapies: A Case Report and Literature Review. [PDF]
Kashimura Y +4 more
europepmc +1 more source
Pancreatic α-cell sodium-glucose cotransporter 1 (SGLT1) does not appear to contribute to hyperglucagonemia and glucose intolerance in diabetic mice. [PDF]
Ikeuchi Y +9 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Emergency Medicine, 2003
AbstractDespite its infrequent usage, glucagon is an important drug in the ED. It has both well established and less well established indications. This article reviews its role for the practising emergency physician.
+7 more sources
AbstractDespite its infrequent usage, glucagon is an important drug in the ED. It has both well established and less well established indications. This article reviews its role for the practising emergency physician.
+7 more sources

